Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioNTech SE's inventories, raw materials & components for the quarter that ended in Jun. 2026 was MXN0 Mil.
BioNTech SE's quarterly raw materials
declined
from Dec. 2025 (MXN2,068 Mil) to Mar. 2026 (MXN0 Mil) but then
stayed the same
from Mar. 2026 (MXN0 Mil) to Jun. 2026 (MXN0 Mil).
BioNTech SE's annual raw materials
declined
from Dec. 2023 (MXN6,432 Mil) to Dec. 2024 (MXN5,855 Mil) and
declined
from Dec. 2024 (MXN5,855 Mil) to Dec. 2025 (MXN2,068 Mil).
BioNTech SE Inventories, Raw Materials & Components Historical Data
* Premium members only.
The historical data trend for BioNTech SE's Inventories, Raw Materials & Components can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNTech SE Inventories, Raw Materials & Components Chart
What does a Inventories, Raw Materials & Components of MXN0 Mil mean?
BioNTech SE (MEX:BNTXN) has a Inventories, Raw Materials & Components of MXN0 Mil as of Jun. 2026. Raw materials are the components a company uses for its main products. View historical data on BioNTech SE and its competitors.
Is BioNTech SE's Inventories, Raw Materials & Components too high?
BioNTech SE's current Inventories, Raw Materials & Components is MXN0 Mil. Overall, BioNTech SE has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioNTech SE's Inventories, Raw Materials & Components compare to INSM and INCY?
BioNTech SE's Inventories, Raw Materials & Components of MXN0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Biotechnology company?
A good Inventories, Raw Materials & Components depends on the Biotechnology industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on BioNTech SE and its competitors. BioNTech SE's current Inventories, Raw Materials & Components is MXN0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNTech SE stock overvalued right now?
Based on GuruFocus' analysis, BioNTech SE (MEX:BNTXN) is currently considered Fairly Valued. The stock's GF Value™ is MXN1,457.90, compared to a current price of MXN1,590.00 — trading 9.1% above its estimated fair value. The current Inventories, Raw Materials & Components is MXN0 Mil. BioNTech SE's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For BioNTech SE (MEX:BNTXN), the current Inventories, Raw Materials & Components is MXN0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNTech SE (MEX:BNTXN) Overvalued in 2026?
Based on GuruFocus' analysis, BioNTech SE stock appears to be overvalued.
The current stock price of MXN1,590.00 is trading 9.1% above its estimated GF Value™ of MXN1,457.90.
GuruFocus considers BioNTech SE to be Fairly Valued.
Key valuation signals for MEX:BNTXN:
Inventories, Raw Materials & Components: MXN0 Mil
GF Value™: MXN1,457.90 vs. price of MXN1,590.00 (9.1% above fair value)
No single metric tells the full story. See the MEX:BNTXN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
54GF Score
Get the complete analysis for MEX:BNTXN
Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BNTXN has been successfully added to your 
